AVL-292 is a Bruton?s tyrosine kinase (BTK) inhibitor that exhibits anticancer chemotherapeutic activities. AVL-292 is in clinical development as a potential treatment for B-cell-related disorders such as chronic lymphocytic leukemia (CLL).
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...


































